Vident Advisory’s Vertex Pharmaceuticals VRTX Stock Holding History

Vident Advisory's VRTX Position: Q1 2026 in Review

Vident Advisory increased its Vertex Pharmaceuticals (VRTX) stake by 17% in Q1 2026, buying an estimated $1.11M and bringing the position to 16,063 shares worth $7.17M. The position accounts for 0.06% of the portfolio, ranked #264.

Vident Advisory first reported a position in VRTX in Q3 2023 and has held it in 11 quarters since. The position peaked at $21.5M in Q1 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

• Vident Advisory held 16,063 shares of Vertex Pharmaceuticals worth $7.17M as of Q1 2026.
• Vident Advisory bought 2,378 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.11M.
• Vertex Pharmaceuticals made up 0.06% of Vident Advisory's portfolio in Q1 2026, its #264 holding.
• Vident Advisory first reported a position in Vertex Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
• Vident Advisory's Vertex Pharmaceuticals position peaked at $21.5M in Q1 2024.
• 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.